Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.42 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31171562 | 0.73 | MEN1 (0.46) | MEN1KMT2ATSHRGAAFUCA1 | |
| SCHEMBL31171610 | 0.73 | MEN1 (0.46) | MEN1KMT2ATSHRGAAFUCA1 | |
| SCHEMBL31171597 | 0.73 | MEN1 (0.46) | MEN1KMT2ATSHRGAAFUCA1 | |
| SCHEMBL21224982 | 0.73 | GAA (0.54) | MEN1KMT2ATSHRGAAMC4R | |
| SCHEMBL31190829 | 0.72 | HSD11B1 (0.39) | TSHRFUCA1SIGMAR1 | |
| SCHEMBL14660884 | 0.71 | MC4R (0.50) | MEN1KMT2ATSHRGAAMC4R | |
| SCHEMBL30748878 | 0.69 | GAA (0.39) | MEN1KMT2ATSHRGAAFUCA1 | |
| SCHEMBL4237488 | 0.69 | GAA (0.54) | MEN1KMT2ATSHRGAAMC4R | |
| SCHEMBL1189223 | 0.69 | MC4R (0.56) | MEN1KMT2AGAAMC4RSIGMAR1 | |
| SCHEMBL15320452 | 0.69 | GAA (0.62) | MEN1KMT2ATSHRGAAMC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4523755-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2025-03-19 | — | — | EP | disclosed |
| EP-4360713-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-10-30 | — | — | EP | disclosed |
| CN-118255772-A | Quinazoline derivatives as antitumor agents | 苏州赞荣医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| EP-4360713-A2 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | F. Hoffmann-La Roche AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| EP-3853220-B1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN LA ROCHE (CH) | 2024-01-03 | — | — | EP | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2023-09-21 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2023-08-15 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | HOFFMANN-LA ROCHE INC. | 2021-12-16 | — | — | US | disclosed |
| WO-2020057511-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | SUZHOU ZANRONG PHARMA LIMITED (CN) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210386742-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | MEN1 2595/4885KMT2A 2461/4885TSHR 2483/4885 |
| US-11723908-B2 | Quinazoline derivatives as antitumor agents | ABL1, TP53, JAK1 | MEN1 2595/4885KMT2A 2461/4885TSHR 2483/4885 |
| US-20230293533-A1 | QUINAZOLINE DERIVATIVES AS ANTITUMOR AGENTS | ABL1, TP53, JAK1 | MEN1 2595/4885KMT2A 2461/4885TSHR 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.